• Tutorial
  • Product Matrix
  • Validate
  • Regulatory
  • ROI
  • News
  • Blog
  • Events
  • References
  • LinkedIn Group
  • Training & Consulting
  • Contact

Rapid Micro Methods News

Our news pages will keep you informed of press releases and news articles on RMM technologies, updates from technology suppliers, reviews of recent publications and presentations, and what's changing in the world of rapid methods. You can also follow our news posts on Twitter, Facebook, LinkedIn and RSS.

Follow us on Twitter Follow us on Facebook LinkedIn RSS Feed

Please click here to submit your news

Friday, October 6, 2017

Bruker Introduces New Products for Diagnosis and Susceptibility Testing of Invasive Fungal Diseases

At the Trends in Medical Mycology conference, Bruker today introduces the new, CE-IVD marked Fungiplex® Candida fast diagnostic assay, a multiplex real-time PCR test for the rapid identification of the most common pathogens associated with invasive candidiasis.  The new Fungiplex Candida assay does not require any culture steps, and typically gives results in just 2-3 hours directly from patient blood, plasma or serum samples.

Bruker also introduces the CE-IVD marked MICRONAUT®-AM (antimycotics) test plate for the automated or manual antifungal susceptibility testing (AFST) of yeasts from cultures. MICRONAUT®-AM is from the product range of recently acquired MERLIN Diagnostika GmbH, a leader in speciality susceptibility testing products across a range of human and veterinary application areas.

The Bruker microbiology portfolio is led by the MALDI Biotyper (MBT) platform for fast proteomic fingerprinting, a market-leading family of products providing rapid, broad-based molecular identification of microorganisms like bacteria, yeasts and fungi from cultures.  Both new IFD tests further expand Bruker's microbiology business, and re-inforce Bruker's additional focus on rapid identification of invasive fungal diseases, followed by antifungal susceptibility testing.

With the previous launch of the CE-IVD marked Fungiplex Aspergillus fast identification assay at ECCMID 2017, Bruker announced a new focus on rapid detection of fungal infections in at-risk patients, especially the immuno-compromised, allowing the development of effective treatment strategies to deliver improved patient outcomes.  Such IFD diagnostic tools have the additional benefits of reducing prophylactic antifungal drug treatments, reducing the likelihood of antifungal resistance and bringing down the overall cost of care for at-risk patients.

The new Fungiplex Candida assay is a multiplex real-time PCR test for the most common pathogens associated with invasive candidiasis (IC), a major cause of morbidity and mortality in health care environments. The sensitivity of blood culture for diagnosing IC is low, typically reported at 50%, and is coupled with slow turnaround times of 2-3 days.  Delayed diagnosis and delays to the initiation of appropriate treatment are associated with high mortality and extended hospital stays.  The Fungiplex Candida assay enables the early identification of Candida infection without the need for blood culture and is validated against DNA extracted from whole blood, serum and plasma.  Fungiplex Candida detects the main causative pathogens of IC: C. albicans, C. parapsilosis, C. tropicalis, C. dubliniensis, and differentiates C. krusei and C. glabrata.

The Fungiplex Candida assay reports the identification results in less than 2 hours from DNA extraction and displays excellent clinical performance, in a user friendly format compatible with existing laboratory equipment. This assay delivers the potential to aid earlier diagnosis, reduce hospital spend and improve patient outcomes.

Dr. Lewis White, Principal Clinical Scientist at NPHS Microbiology Cardiff, commented on the new Fungiplex Candida assay: "Fungal diseases such as invasive candidiasis pose an extremely serious healthcare risk to immunosuppressed patients, especially within the intensive care unit. Current diagnostic methods, including culture, struggle due to low sensitivity. Expensive prophylactic and empiric drug use is common, whereas PCR, as a key component of combined biomarker surveillance strategies, has the potential to prevent the overuse of unnecessary antifungals and allows the targeted use of antifungal drugs. Bruker's Fungiplex Candida real-time PCR assay, when combined with appropriate recommendations on DNA extraction, provides a standardised approach that displays excellent analytical performance and clinical sensitivity and specificity, with the potential to improve the diagnosis and treatment of at-risk patients. With the standardization of Candida PCR previously lacking, this new commercial option provides users with a validated and quality controlled alternative to be used in combination with serological tests."

The principle of the MICRONAUT™ system for specialty antimicrobial susceptibility testing is the phenotypic detection of microbial growth inhibition in the presence of antibiotics.  Its microdilution procedure is a standardized, globally accepted reference method for the determination of minimal inhibitory concentrations (MICs).  The MICRONAUT-AM plate allows for the antifungal susceptibility testing (AFST) of nine antimycotics (including anidulafungin, caspofungin and posaconazol) in up to eleven concentrations, and provides a standardized workflow for analysis with visual or photometric interpretation.

Dr. David Eustace, Head of IFD Business Unit at Bruker Daltonics, added: "The combination of the Fungiplex Candida and Fungiplex Aspergillusreal-time PCR assays for the rapid detection of IFDs without culture, coupled with the introduction of MICRONAUT-AM high-performance MIC-based antimycotic susceptibility products, complement the existing MALDI Biotyper product family in the field of invasive fungal disease testing.  This expanding IFD portfolio has the capability of meeting a wide range of customer needs, delivering high quality solutions to improve patient outcomes at every stage of the IFD treatment pathway."

About the Bruker MALDI Biotyper (MBT) Platform

The MALDI Biotyper family of systems enables molecular identification of microorganisms like bacteria, yeasts and fungi.  Classification and identification of microorganisms is achieved reliably and quickly using proteomic fingerprinting by high-throughput MALDI-TOF mass spectrometry.  The MALDI Biotyper uses a molecular approach based on specific proteomic fingerprints from bacterial strains.  Many published studies have highlighted the greater accuracy and lower cost offered, as well as typically much faster time-to-result (TTR).

Applications of various MALDI Biotyper solutions include clinical routine microbial identification, environmental and pharmaceutical analysis, taxonomical research, food and consumer product safety and quality control, as well as marine microbiology.  In many European and international laboratories the MALDI Biotyper has replaced classical biochemical testing for bacterial identification in the past few years due to the accuracy, speed, extensive species coverage, ease of use and cost effectiveness of the system.  Traditional biochemical techniques detect different metabolic properties of microorganisms, can take many hours or even days for completion, and they often lack specificity.

The robust MALDI Biotyper requires minimal sample preparation and offers low consumables cost.  The products of the MALDI Biotyper family are available in a research-use-only (RUO) version, as the U.S. FDA-cleared MALDI Biotyper CA System, or in an IVD-CE version according to EU directive EC/98/79.  The MALDI Biotyper also has medical device registrations in numerous other countries.  RUO versions of the MALDI Biotyper allow selected, high-value antimicrobial resistance tests.
Posted by RapidMicro at 6:23 AM

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)
  • Click to Show All News Articles

Search for News





News Archive

  • ►  2019 (10)
    • ►  February (6)
    • ►  January (4)
  • ►  2018 (187)
    • ►  December (9)
    • ►  November (16)
    • ►  October (15)
    • ►  September (14)
    • ►  August (18)
    • ►  July (9)
    • ►  June (24)
    • ►  May (13)
    • ►  April (15)
    • ►  March (20)
    • ►  February (19)
    • ►  January (15)
  • ▼  2017 (115)
    • ►  December (9)
    • ►  November (15)
    • ▼  October (10)
      • Generex Announces Distribution Contract For Rapid ...
      • GenePOC Launches its new GenePOC™ GBS DS Test
      • Abacus Diagnostica Receives CE Mark for the World'...
      • Market Ready HIV Self-Test Gets the Thumbs Up from...
      • Roche C. difficile Assay Among FDA-Cleared Tests i...
      • Bruker Introduces New Products for Diagnosis and S...
      • Hologic Panther Fusion Flu A/B/RSV Assay Cleared b...
      • Cepheid Xpress Strep A Test Clears FDA
      • Accurate Salmonella Test Gives Veterinarians Quick...
      • Alere Receives FDA Clearance for Alere™ i Influenz...
    • ►  September (8)
    • ►  August (17)
    • ►  July (12)
    • ►  June (5)
    • ►  May (4)
    • ►  April (11)
    • ►  March (6)
    • ►  February (12)
    • ►  January (6)
  • ►  2016 (127)
    • ►  December (12)
    • ►  November (17)
    • ►  October (11)
    • ►  August (19)
    • ►  July (7)
    • ►  June (16)
    • ►  May (13)
    • ►  April (7)
    • ►  March (8)
    • ►  February (17)
  • ►  2015 (187)
    • ►  December (12)
    • ►  November (12)
    • ►  October (17)
    • ►  September (20)
    • ►  August (10)
    • ►  July (20)
    • ►  June (7)
    • ►  May (11)
    • ►  April (19)
    • ►  March (21)
    • ►  February (23)
    • ►  January (15)
  • ►  2014 (199)
    • ►  December (22)
    • ►  November (16)
    • ►  October (28)
    • ►  September (19)
    • ►  August (11)
    • ►  July (13)
    • ►  June (11)
    • ►  May (17)
    • ►  April (13)
    • ►  March (13)
    • ►  February (19)
    • ►  January (17)
  • ►  2013 (229)
    • ►  December (14)
    • ►  November (20)
    • ►  October (15)
    • ►  September (18)
    • ►  August (8)
    • ►  July (31)
    • ►  June (21)
    • ►  May (18)
    • ►  April (22)
    • ►  March (20)
    • ►  February (15)
    • ►  January (27)
  • ►  2012 (262)
    • ►  December (17)
    • ►  November (26)
    • ►  October (18)
    • ►  September (15)
    • ►  August (22)
    • ►  July (18)
    • ►  June (29)
    • ►  May (23)
    • ►  April (26)
    • ►  March (29)
    • ►  February (20)
    • ►  January (19)
  • ►  2011 (180)
    • ►  December (19)
    • ►  November (15)
    • ►  October (23)
    • ►  September (15)
    • ►  August (20)
    • ►  July (13)
    • ►  June (24)
    • ►  May (16)
    • ►  April (10)
    • ►  March (3)
    • ►  February (14)
    • ►  January (8)
  • ►  2010 (53)
    • ►  December (7)
    • ►  November (8)
    • ►  October (9)
    • ►  September (15)
    • ►  August (3)
    • ►  July (3)
    • ►  June (8)

Popular News Articles

  • Abbott Discontinuing Current Version of Plex-ID PCR System for Smaller Platform Under Development
    Abbott is discontinuing the current version of the Plex-ID system as it prepares for market a next-generation system intended to be smaller...
  • FDA Grants CLIA Waiver Expanding the Availability of Rapid Screening Test for Syphilis
    The U.S. Food and Drug Administration today announced that it granted the first-ever waiver, under certain laboratory regulations, for a rap...
  • DNA Extraction from Samples in a Minute
    Scientists at the Agharkar Research Institute (ARI) in Pune have developed a novel technology to extract bacterial DNA in just a minute from...
  • RPS Announces CE Mark of Rapid Point-Of-Care Test to Help Detect the Body's Immune Response to Viral And Bacterial Infections
    RPS Diagnostics Inc. (RPS®) announced CE mark of its FebriDx™ test clearing the way for sales in the European Union and all countries recogn...
  • Chembio Signs Agreement With CDC Contractor to Develop a Multiplex Point-of-Care Test for Influenza Immunity
    Chembio Diagnostics, Inc., a leader in point-of-care (POC) diagnostic tests for infectious diseases, today announced that it has entered int...
  • A High-Tech Real-Time Solution for Detecting Bacteria in Water
    Water quality and safety can never be taken for granted. Every day, millions of tons of inadequately treated sewage, industrial and agricult...
  • Escherichia coli Serotype O104:H4 Quality Control Strain Now Available from Microbiologics
    Leading biomaterial manufacturer, Microbiologics, has added a new strain of Shiga-toxin producing Escherichia coli (STEC) to their line o...
  • 3M Debuts Food Safety Molecular Detection Assay for Listeria monocytogenes
    The new 3M molecular detection assay for Listeria monocytogenes is the fourth test available for the 3M molecular detection system, which ...
  • MilliporeSigma Acquires BioControl to Strengthen Position in Food Safety Testing
    MilliporeSigma today announced it has acquired BioControl Systems Inc., a global leader in food safety testing. The acquisition opens grow...
  • Devices for Detecting Pathogens in Food on the Production Line
    CIC microGUNE is developing the PREDETEC project, which aims to produce sensors capable of locating infectious agents in food, thanks to the...

Links

  • Microbiology Consultants, LLC
© Copyright 2010-2019 rapidmicromethods.com. All rights reserved. • Terms of Use • Advertise
LinkedIn  LinkedIn   Follow RapidMicro on Twitter  Twitter   Follow RapidMicro on Facebook  Facebook